Presentation is loading. Please wait.

Presentation is loading. Please wait.

Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 

Similar presentations


Presentation on theme: "Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) "— Presentation transcript:

1 Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA)  Sonata Jodele, MD, Benjamin Laskin, MD, MS, Tsuyoshi Fukuda, PhD, Alexander Vinks, PharmD, PhD, FCP, Kana Mizuno, Jens Goebel, MD, Kasiani C. Myers, MD, Jack Bleesing, MD, PhD, Michael S. Grimley, MD, Javier El-Bietar, MD, Christopher E. Dandoy, MD, MSc, Ashley Teusink, PharmD, MBA, BCPS, Adam Lane, PhD, Stella M. Davies, MBBS, PhD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S225-S226 (February 2015) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure Overall survival in HSCT patients with high risk TMA
Biology of Blood and Marrow Transplantation  , S225-S226DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) "

Similar presentations


Ads by Google